PointState Capital’s Amedisys AMED Stock Holding History

PointState Capital’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-15,000	Closed	-$2.43M	–	71
2021 Q4	$2.43M	Buy	+15,000	New	+$2.41M	0.04%	105

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

PointState Capital's AMED Position: Q1 2022 in Review

PointState Capital sold out of Amedisys (AMED) in Q1 2022, closing a stake of 15,000 shares — an estimated $2.43M sold.

PointState Capital first reported a position in AMED in Q4 2021 and held it in 1 quarter. The position peaked at $2.43M in Q4 2021. 328 funds tracked by Wall St. Rank hold AMED as of Q1 2022.

PointState Capital reported no remaining Amedisys position as of Q1 2022 after selling out during the quarter.
PointState Capital sold 15,000 Amedisys shares in Q1 2022, an estimated $2.43M.
PointState Capital first reported a position in Amedisys in Q4 2021 and held it in 1 quarter.
PointState Capital's Amedisys position peaked at $2.43M in Q4 2021.
328 funds tracked by Wall St. Rank held Amedisys as of Q1 2022.

Based on PointState Capital's 13F filing for Q1 2022, filed 13 May 2022.